Prevalence of Serotonergic Drug Use in Patients Exposed to Perioperative Methylene Blue: A Cross-Sectional Study (2025)

Peer-Reviewed Study · McMillan E, Meepagala S, Ogbutor K, et al. · March 24, 2025

McMillan E et al., 2025-03-24: Cross-sectional analysis of electronic health records finding that about one in ten patients given perioperative methylene blue was also on a serotonergic drug, the population at risk of serotonin syndrome.

The large database analysis revealed that among the 249,131 patients who received perioperative methylene blue, 25,282 (10.14%) were concomitantly given serotonergic drugs. By drug class, SSRIs had the highest concomitant use with 15,705 cases and a prevalence of 63.04/1000 cases.

McMillan E et al., 2025-03-24: Cross-sectional analysis of electronic health records finding that about one in ten patients given perioperative methylene blue was also on a serotonergic drug, the population at risk of serotonin syndrome. Study type: retrospective cross-sectional database study (TriNetX, 97 organisations). N=249,131 MB-exposed patients. Country: USA. Perioperative MB; dose not analysed. Funding/conflicts: not stated. Comparator: none. Bearing CONTRADICTS "low risk of drug interactions": the exposed population is large and commonly co-prescribed serotonergic drugs. Study type: other.